Answers are grounded in this paper and cite their sources.
Lumen-apposing metal stents (LAMS) have been recently developed to improve treatment outcomes in the endoscopic management of pancreatic fluid collections (PFC), particularly in walled-off necrosis (WON), to facilitate better drainage of necrotic contents and minimise the risk of perforation and peritoneal leakage. In an ongoing randomised trial, we observed serious adverse events that included delayed bleeding, buried stent syndrome and biliary stricture that necessitated a change in the management protocol for patients with PFC treated with LAMS.
No takes yet. Share an insight, caveat, or question.
Bang et al. (2016) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: